Clinical trial
Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in…
NCT00402363 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00402363 |
|---|---|
| Title | Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fibrillation, Atrial |
| Intervention type | Drug |
| Interventions | omega-3-acid ethyl esters, Placebo |
| Enrollment | 663 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Nov 22, 2006 |
| Last update posted | Jan 30, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: